Dabur India has acquired 72.15% of Fem Care Pharma Ltd (FCPL), a leading player in the women`s skin care products market, for Rs2.03bn in an all-cash deal. Dabur India Ltd has announced the acquisition of 72.15% of Fem Care Pharma Ltd (FCPL), a leading player in the women’s skin care products market, for Rs2.03bn in an all-cash deal.

The board of directors of Dabur India Ltd approved the acquisition at a board meeting held in Mumbai today. The transaction ascribes a price per share of Rs800, which translates into an equity valuation of Rs2.82bn and an enterprise valuation of around Rs3bn of Fem Care Pharma Ltd. Dabur will make an open offer for an additional 20% shares in the Company as required under the takeover regulations.

“Acquisition of Fem Care Pharma is in line with our strategy to aggressively expand Dabur’s scale of operations and strengthen its presence in the fast moving consumer goods (FMCG) space. This transaction would give Dabur an entry into the high-growth skin care market with an established brand name ‘FEM’. Further, Dabur also has the potential to extend the brand into newer and related skin care categories,” said Dr. Anand Burman, Chairman, Dabur India Ltd.

Fem Care Pharma Ltd, which has a leadership position in the fairness bleach category and a strong market position in hair removal and liquid soap category, is best known for its brand ‘FEM’. The other brands in its portfolio include Oxybleach cream, Botanica anti-ageing cream, Stratum colour protecting hair conditioners, SAKA men’s bleach and Bambi fabric softeners.

FCPL, which reported a consolidated net profit of Rs97.5mn in the first half of the 2008-09 fiscal on a turnover of Rs544.5mn, also has a sizeable international market presence in markets such as Yemen, Maldives, Mauritius, Malaysia, UAE, Oman etc.

“The acquisition brings to Dabur a portfolio of well-known household brands that enjoy a pole position in their respective categories, offering us a strong platform to enter newer product categories and markets. Fem’s brands fit in well with Dabur’s future growth plans, both for India and international markets. As with our previous acquisition and subsequent integration of Balsara’s Hygiene and Home products businesses, the Fem Care Pharma Ltd transaction too would offer substantial synergies for expanding the reach of Fem’s brands in all our geographies as well as better management of overall system costs,” said Sunil Duggal, CEO, Dabur India Ltd.

“The strengths of Dabur will help expand the distribution of Fem’s brands across India and fuel faster growth for the company, both in India and abroad, thereby enhancing shareholder value,” said Sunita Ramnathkar, Joint Managing Director, Fem Care Pharma Ltd.

“As Dabur gains access to Fem’s research capabilities, we believe it will be able to broaden the company’s product portfolio and further capitalize on the emerging opportunities in domestic and international markets,” said Sunil H. Pophale, Chairman & Managing Director, Fem Care Pharma Ltd.

KPMG Corporate Finance was the financial advisor to the promoters of Fem Care Pharma Ltd and Ambit Corporate Finance was the financial advisor to Dabur India Ltd.

source: Indiainfoline

Tags: calls, daytrading, free calls, intraday, tips

Similar Posts:

• Dabur buys Ajanta Pharma capsule brand, focus on OTC healthcare
• Fresenius Kabi has closed the acquisition of Dabur Pharma
• Dabur Pharma signs agreement with GPO, Thailand
• Dabur Pharma launches Irinotecan Hydrochloride Injection
• GCPL to acquire Kinky